STOCK TITAN

Organogenesis Holdings (ORGO) 10-K Filings

ORGO NASDAQ

Here are the 10-K annual reports from Organogenesis Holdings Inc. (ORGO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.

Rhea-AI Summary

Organogenesis Holdings Inc. provides an in‑depth look at its regenerative medicine business, focused on advanced wound care and surgical and sports medicine products like Apligraf, Dermagraft, PuraPly, NuShield, Affinity, Novachor and ReNu.

The company outlines major shifts in Medicare and CMS policy for skin substitutes, including new 2026 payment structures and the WISeR prior‑authorization model, which are already contributing to a significant year‑over‑year revenue decline in early 2026 and may pressure future utilization and profitability.

Organogenesis also highlights mixed but generally supportive Phase 3 data for its ReNu osteoarthritis program and the start of a rolling BLA, plus a long‑term lease for a new Smithfield, Rhode Island biomanufacturing facility intended to bring Dermagraft production back online and expand capacity from 2027.